Table 4 Stem cell transplant and engraftment following high-dose chemotherapy and rescue with HSCs mobilized with MGTA-145 and plerixafor.

From: Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma

Variable

N (%) or median (range)

Patients undergoing transplant with MGTA-145 and plerixafor mobilized HSCsa

19

Conditioning for ASCT

 Melphalan 200 mg/m2

16 (84%)

 Melphalan 140 mg/m2

3 (16%)

CD34+ cells/kg infused, median (range):

3.4 × 106 cells/kg (2.2–8.1)

Engraftment

Successful primary engraftment

19 (100%)

Durable engraftment at day 100

19 (100%)

Neutrophil engraftment, ANC ≥ 500 × 106/L

12 days (11–15)

Platelet engraftment ≥ 20,000 × 106/L without transfusion in 7 days

18 days (15–33)

Platelet engraftment ≥ 50,000 × 106/L

20 days (13–44)

RBC transfusions needed during ASCT

3 (16%)

Poor graft function**

1

  1. a4 patients on study underwent transplant with G-CSF and plerixafor mobilized HSCs due to failure to collect adequate HSCs with GCSF and plerixafor (n = 3) or clotting of stem cell product during cryopreservation (n = 1)
  2. b One patient with slow count recovery. This patient received stem cell boost at day 36 with 1.9 million CD34+ cells/kg. Primary neutrophil engraftment was on day 14 and primary platelet engraftment was on day 33 post stem cell transplant.
Back to article page